Tofacitinib versus thalidomide for mucocutaneous lesions of systemic lupus erythematosus: A real-world CSTAR cohort study XXVII
Tofacitinib might be superior to thalidomide in the improvement of mucocutaneous and musculoskeletal lesions in SLE, and had a good safety profile.
Authors
- Xinwang Duan (ORCID: https://orcid.org/0000-0002-0432-3638)
- Yunzhuan Chen
- Xinping Tian (ORCID: https://orcid.org/0000-0002-1511-7952)
- Mengtao Li (ORCID: https://orcid.org/0000-0003-4252-2889)
- Yuehong Huo
- Leyao Ma (ORCID: https://orcid.org/0009-0003-4512-0700)
- Qian Wang (ORCID: https://orcid.org/0000-0002-4541-9898)
- Zhao Man (ORCID: https://orcid.org/0009-0003-2250-4090)
- Zhaohui Zheng (ORCID: https://orcid.org/0000-0001-7804-4474)
- Shengyun Liu (ORCID: https://orcid.org/0000-0003-3197-3158)
- Cheng Zhao (ORCID: https://orcid.org/0000-0003-3435-1493)
Institutions
- Ministry of Education of the People's Republic of China (CN)
- Nanchang University (CN)
- Guangxi Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- Second Affiliated Hospital of Nanchang University (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Zhengzhou People's Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Xijing Hospital (CN)
- Shanxi Datong University (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Lupus
- Published
- 2024-08-08
- DOI
- https://doi.org/10.1177/09612033241272953
- Citations
- 2
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Beijing Municipal Science and Technology Commission